Integrin α6 β4 on Circulating Tumor Cells of Metastatic Breast Cancer Patients.

Circulating tumor cells epithelial-to-mesenchymal transition metastatic breast cancer α6 β4 integrin

Journal

Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897

Informations de publication

Date de publication:
2021
Historique:
received: 03 04 2021
revised: 26 05 2021
accepted: 02 06 2021
entrez: 3 9 2021
pubmed: 4 9 2021
medline: 4 9 2021
Statut: epublish

Résumé

The detection of circulating tumor cells (CTCs) is prognostic during the disease in women with metastatic breast cancer. Integrins are key role players in nearly every step of cancer progression. In this study, we aimed to analyze integrin alpha6beta4 expression on CTCs isolated from blood samples of patients with advanced breast cancer. In this single-center study, peripheral blood samples from 23 breast cancer patients were obtained and analyzed for the presence of CTCs by EasySep™ Direct Human CTC Enrichment Kit combined with subsequent immunocytochemical staining of anti-cytokeratin and anti-epithelial cell adhesion molecules, and β4 integrin on CTCs. Data were correlated with clinicopathological parameters. CTCs were detected in 100% of the patients. The ratio of integrin β4+ CTC was 61% ± 8% of total CTCs. No significant correlation between histopathological parameters and CTC detection was found. Our results demonstrated the importance of α6 β4 integrin expression on CTCs in distant metastasis.

Sections du résumé

BACKGROUND BACKGROUND
The detection of circulating tumor cells (CTCs) is prognostic during the disease in women with metastatic breast cancer. Integrins are key role players in nearly every step of cancer progression. In this study, we aimed to analyze integrin alpha6beta4 expression on CTCs isolated from blood samples of patients with advanced breast cancer.
MATERIALS AND METHODS METHODS
In this single-center study, peripheral blood samples from 23 breast cancer patients were obtained and analyzed for the presence of CTCs by EasySep™ Direct Human CTC Enrichment Kit combined with subsequent immunocytochemical staining of anti-cytokeratin and anti-epithelial cell adhesion molecules, and β4 integrin on CTCs. Data were correlated with clinicopathological parameters.
RESULTS RESULTS
CTCs were detected in 100% of the patients. The ratio of integrin β4+ CTC was 61% ± 8% of total CTCs. No significant correlation between histopathological parameters and CTC detection was found.
CONCLUSION CONCLUSIONS
Our results demonstrated the importance of α6 β4 integrin expression on CTCs in distant metastasis.

Identifiants

pubmed: 34476224
doi: 10.4103/abr.abr_76_21
pii: ABR-10-16
pmc: PMC8378442
doi:

Types de publication

Journal Article

Langues

eng

Pagination

16

Informations de copyright

Copyright: © 2021 Advanced Biomedical Research.

Déclaration de conflit d'intérêts

There are no conflicts of interest.

Références

Cancer Cell. 2019 Mar 18;35(3):347-367
pubmed: 30889378
Sci Rep. 2017 Jan 13;7:40464
pubmed: 28084395
Stem Cells Dev. 2017 Aug 1;26(15):1090-1099
pubmed: 28494695
Mod Pathol. 2007 Jun;20(6):656-67
pubmed: 17415382
Clin Cancer Res. 1998 Feb;4(2):407-10
pubmed: 9516929
Cancer Res. 2020 Feb 15;80(4):771-783
pubmed: 31843981
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):80-6
pubmed: 19124484
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Cancers (Basel). 2020 Apr 20;12(4):
pubmed: 32326109
Clin Cancer Res. 2008 Feb 15;14(4):1050-8
pubmed: 18281537
Stem Cell Res Ther. 2018 May 2;9(1):122
pubmed: 29720266
Lab Invest. 2015 Sep;95(9):976-86
pubmed: 26121317
Mol Biol Cell. 2007 Nov;18(11):4210-21
pubmed: 17699601
Mod Pathol. 2005 Sep;18(9):1165-75
pubmed: 15920552

Auteurs

Mehran Sharifi (M)

Cancer Prevention Research Center, Isfahan Medical School, Isfahan University of Medical Science, Isfahan, Iran.

Bahareh Zarrin (B)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Majed Bahri Najafi (M)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Mohamad Reza Hakimian (MR)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Nastaran Hosseini (N)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Kasra Talebi (K)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Shaghayegh Haghjooy Javanmard (SH)

Applied Physiology Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Classifications MeSH